GÖRG advises Heidelberg Pharma AG on a private placement with gross proceeds of EUR 20 million

Munich, 21.06.2021

GÖRG Partnerschaft von Rechtsanwälten mbB advised Heidelberg Pharma AG on a capital increase with gross proceeds of EUR 20 million under the leadership of Munich partner Dr. Bernt Paudtke. 

The capital increase based on resolutions of 15 June 2021 represents approximately 10% of the company’s out-standing share capital and will increase the total number of shares to 34,173,009. The 3,106,637 new shares were placed exclusively with ew biotech specialist institutional investors, including Polar Capital Biotech Investment Fund, Invus and DH-LT-Investments GmbH, an investment company of Mr. Dietmar Hopp, amongst others, via an accelerated book building transaction and will be admitted to trading on the Frankfurt Stock Exchange. The issue price was EUR 6.44 per share, resulting in gross proceeds of EUR 20 million for Heidelberg Pharma AG.

The capital increase has been executed by Bryan, Garnier & Co acting as global coordinator and sole bookrunner.
 

Advisors Heidelberg Pharma 

GÖRG Partnerschaft von Rechtsanwälten mbB
Dr. Bernt Paudtke, Partner, M&A / Corporate, Munich 
Dr. Christian Glauer, Associated Partner, M&A / Corporate, Munich 
Tobias Reichenberger, Associate, M&A / Corporate, Munich

Legal Department Heidelberg Pharma AG 
Mikaela Dimitropoulos (Director Legal, HR & IP)

Advisors Bryan, Garnier & Co

Pinsent Masons Partnerschaft von Rechtsanwälten mbB
Dr. Susanne Lenz, LL.M. (University of Pennsylvania), Partner, M&A / Corporate, Frankfurt am Main
Dušan Stojković, Senior Associate, M&A / Corporate, Frankfurt am Main 
Sara Šepac, Associate, M&A / Corporate, Frankfurt am Main

    
About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6.
 

 Newsletter Icon

We inform you about current legal developments in the areas relevant to you.

Subscribe to our Newsletter

Anmedlung Newsletter